INCREASING PREGNANCY RATES
The invention relates to a stable formulation for controlling oestrus in a subject. The formulation comprises Gonadotrophin Releasing Hormone or an acceptable salt or analogue thereof, progesterone or an analogue thereof, and an acceptable carrier.
1 . A formulation comprising:
Gonadotrophin Releasing Hormone or an acceptable salt or analogue thereof;
progesterone or an analogue thereof; and
an acceptable carrier.
2 . The formulation of claim 1 , said formulation being selected from the group consisting of a solution, a micellar solution, a microemulsion, a miniemulsion or a small particle size emulsion.
3 . (canceled)
4 . The formulation of claim 1 , said formulation being sterile.
5 . The formulation of claim 4 , said formulation being acceptable for injection.
6 . The formulation of claim 1 wherein the progesterone or analogue is present in the formulation between about 25 mg/ml and about 150 mg/ml.
7 . The formulation of claim 1 wherein the Gonadotrophin Releasing Hormone or salt or analogue thereof is present in the formulation between about 0.02 mg/ml and about 0.1 mg/ml.
8 . The formulation of claim 1 additionally comprising water.
9 . The formulation of claim 8 wherein the water is present between about 2 mg/ml and about 50 mg/ml.
10 . The formulation of claim 1 wherein the carrier is a solvent for the progesterone or analogue thereof, or for the Gonadotrophin Releasing Hormone or salt or analogue thereof, or for both.
11 . (canceled)
12 . The formulation of claim 1 additionally comprising an antioxidant.
13 . The formulation of claim 1 wherein the formulation has a pH of between about 4 and about 5.
14 . The formulation of claim 1 wherein the the formulation additionally comprises phosphoric acid.
15 . (canceled)
16 . A unit dose, said unit dose comprising between about 1 ml and about 20 ml of a formulation comprising:
Gonadotrophin Releasing Hormone or an acceptable salt or analogue thereof;
progesterone or an analogue thereof; and
an acceptable carrier.
17 . The unit dose of claim 16 comprising between about 2 ml and about 5 ml of the formulation.
18 . The unit dose of claim 16 , said unit dose being sterile.
19 . The unit dose of claim 16 , said unit dose being housed within a container, said container having a sufficient volume for the required quantity of the formulation.
20 . (canceled)
21 . A process for making a formulation comprising combining:
a solution comprising Gonadotrophin Releasing Hormone or an acceptable salt or analogue thereof dissolved in water,
a solvent, and
progesterone or an analogue thereof.
22 - 34 . (canceled)
35 . A method for increasing the probability that a female animal becomes pregnant, comprising administering to said animal a unit dose of a formulation on day 1, said formulation comprising:
Gonadotrophin Releasing Hormone or an acceptable salt or analogue thereof;
progesterone or an analogue thereof; and
an acceptable carrier.
36 . The method of claim 35 additionally comprising administering to the animal prostaglandin, or an analogue thereof having similar biological activity, on day 7.
37 . The method of claim 36 additionally comprising administering Gonadotrophin Releasing Hormone or an analogue or salt thereof on day 9.
38 . The method of claim 35 wherein artificial insemination is conducted on day 9 or 10.
39 . The method of claim 35 wherein the administering occurs during or following a hormone intervention program.
40 . The formulation of claim 1 wherein the Gonadotrophin Releasing Hormone or an acceptable salt or analogue thereof is selected from the group consisting of: buserelin, deslorelin, avorelin, leuprolide, natural luteinizing hormone releasing hormone, triptorelin, nafarelin, goselerin, fertirelin or salts thereof.
41 . The unit dose of claim 16 comprising about 5 ml of the formulation.